If you search CRO in Argentina or CRO en Argentina, you should land on the First-in-Human CRO that already works the ANMAT file — not a brochure that mixes a 90-business-day statutory target with a commercial registration quote.
bioaccess® is that CRO. Headquarters in Miami. ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the federal authority on the clinical-trial file. Independent ethics committees and provincial oversight (Buenos Aires and beyond) sit beside it. We run clinical trials in Argentina.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia, Paraguay, and Venezuela are sibling country categories. We still run trials in those countries. Argentina is not a replacement for any of them.
What “CRO in Argentina” has to mean
An Argentina CRO for first-in-human devices is not a Latin America slide and a courier account. It is a company that can file with ANMAT in Spanish, sit the independent ethics committee, file the provincial dossier in parallel, keep investigational import moving, and stay in the room after first patient in.
That is why this page answers CRO in Argentina / CRO en Argentina as a category, and why the trial hub does not invent a named Argentine company. llms-full.txt already lists a Buenos Aires regional office among the published regional desks. The live ANMAT medical-device registration checklist already says bioaccess® serves as local authorized representative / Technical Director for market access. That is a registration fact. It is not a hospital we operate, and it is not a reason to mix a commercial file into a first-in-human quote.
- Miami headquarters — sponsor desk on US Eastern time. Buenos Aires is already listed as a regional office in llms-full.txt.
- ANMAT — Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, already named on the Argentina hub and in llms.txt.
- 90-business-day statutory review target — already on the hub. Clock pauses for RFIs. FIH/EFS device studies often exceed it.
- ~30% lower versus typical US/EU programs — experience since 2010, not a formal study. Already on the hub. llms.txt already records 15+ years of hands-on ANMAT work.
- 21 CFR 812.28 — eligibility for FDA submission and review is not clearance or approval.
Global Phase 3 networks can list Argentina. They rarely hold the ANMAT first-in-human device file and the provincial dossier on one clock. A teaching hospital can enroll. That hospital is not the CRO.
We run trials in Argentina
The category is: who is the CRO in Argentina, and are they actually running studies. We are. We still will. If you are choosing a CRO en Argentina in 2026, ask whether the firm owns the ANMAT clock now — not whether the country is “experienced enough.”
ANMAT review can move, stall, or come back with questions. The hub already says the 90-business-day clock pauses for agency queries, and that first-in-human and early-feasibility device studies commonly exceed the target. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works ANMAT treats delay as responses, ethics alignment, provincial filings, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across ANMAT, ethics, provinces, sites, insurance, importation, monitoring, and safety.
ANMAT clinical trial: the file, not the myth
ANMAT is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. It is Argentina’s national authority for medicines, medical devices, and clinical research. I am not inventing a PAHO/WHO Level 4 badge for ANMAT. llms.txt lists Argentina as “ANMAT.” Level 4 is not on that list, and I will not put it here. This hub also does not claim ICH membership. I will not invent that either.
The live process article — ANMAT clinical trial requirements in Argentina — already names the instruments behind the file: Disposición 6677/2010 (GCP framework for drug trials), Ley 26.529 (Patient Rights Act — informed consent, rights, confidentiality), Disposición 4457/2006 and its 2019 update (medical-device clinical investigation pathway), and Disposición 969/1997 and successor updates (GMP / manufacturing evidence). Those are already-published names. They are not a promise that your protocol clears in 90 business days on the wall clock.
The same article already describes a Buenos Aires + Rosario site network and a median time to first patient in of 5.1 months on the last six ANMAT-authorized studies it cites. I am repeating a published number. I am not putting a new median on the country hub. The hub clock stays the 90-business-day statutory target with pauses. Ask for a study-specific calendar.
Ethics and the provinces sit beside ANMAT — not after you remember them
An independent ethics committee must approve each protocol under ISO 14155. Argentine provinces — most notably Buenos Aires — provide additional jurisdictional oversight. The live ANMAT requirements article already says every site outside CABA (Ciudad Autónoma de Buenos Aires) needs provincial authorization on top of ANMAT, and it already names Buenos Aires Province, Córdoba (COEIS), and Mendoza as the provinces sponsors meet most often. Filing federal, provincial, and CEI dossiers in parallel is the way that article already describes. Filing them one after another adds time. That is a file problem.
The same article already puts CEI first-pass review in a 30–50 day band. The hub does not print a separate ethics-week tile, and I will not invent one here. ISO 14155 and the Declaration of Helsinki are already the study standards on the hub.
ANMAT registration is a second file — keep it off the trial clock
Clinical-trial authorization and commercial device registration are different files. The live ANMAT checklist already describes Classes I–IV under Disposición ANMAT N° 64/2025, the simplified DDJJ route for CE-marked Class I/II through HELENA, full technical evaluation for Classes III and IV, and the local authorized representative plus Technical Director role. Disposición 4446/2025 (effective August 2025) is already on that page as a 48-hour post-nationalization import notice for Class I and II registered devices — a commercial-supply fact, not a first-in-human permit.
If you later want to sell in Argentina, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
Radiopharmaceutical and theranostics work already on the hub
The Argentina hub already states that bioaccess® supports first-in-human radiopharmaceutical and theranostics studies in Argentina — including Lu-177, Ac-225, and Ga-68 programs — under the same ANMAT + independent ethics pathway, to ISO 14155, with data eligible for FDA submission under 21 CFR 812.28. I am not adding a new isotope list. See radiopharmaceuticals.
FDA use of Argentine first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs Argentina studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification — under ISO 14155 with ANMAT authorization and ethics approval.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the number already on the hub
The Argentina hub already publishes ~30% lower versus a comparable US or EU program. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study. llms.txt already records 15+ years of hands-on ANMAT work. Actual cost depends on device complexity, indication, monitoring intensity, and sample size.
Questions a sponsor should ask any CRO in Argentina
- Are you running clinical trials in Argentina now — not “historically”?
- Who owns the ANMAT clock when the file sits, including RFI pauses?
- Can you file the federal package, the CEI package, and the provincial dossier in parallel?
- Do you treat the 90-business-day statutory target as a guarantee, or as the planning target already on the hub?
- Do you claim ANMAT is PAHO/WHO Level 4, or an ICH member, when the live hub does not?
- Do you claim to operate a named Argentine hospital, or do you contract sites?
- Is ANMAT registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ and a published Buenos Aires regional office; ANMAT, ethics, and provinces owned as a file problem; 90-business-day target kept as already published; no Level 4 or ICH-member badge invented; registration kept as a separate market-access file; radiopharma pathway already on the hub; FDA conversation designed in from day one.
How Argentina sits next to Colombia, Paraguay, and Venezuela
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Paraguay has DINAVISA and its own hub. Venezuela has INHRR and its own hub. Argentina is a sibling country category. INVIMA stays INVIMA. DINAVISA stays DINAVISA. INHRR stays INHRR. ANMAT stays ANMAT. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Argentina, clinical trials in Paraguay, clinical trials in Colombia, and clinical trials in Venezuela.
How to start
If you need a CRO in Argentina / CRO en Argentina for a first-in-human or early-feasibility device study — or a radiopharmaceutical / theranostics program, or the separate ANMAT registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, whether you also need an Argentine market-access file, and whether the study is a Lu-177, Ac-225, or Ga-68 program already in the published list. We will tell you how the ANMAT clock would run. We will not tell you to leave the country. We will not invent a Level 4 badge, an ICH-member claim, a hospital we operate, or a day-count we have not already published.
Leave a Reply